Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5219_Библиотеки_им_академика_М_И_Перельмана.pdf
322
A. Jha and A. Kumar
Taiwan (Cleveland etal. 2015; Marchetti etal. 2004). The most important causal
elements for Candidemia include intravascular catheters, parental hyper alimentation, and use of broad spectrum antibiotics. It has been discovered that not just
C.albicans, but NAC (non albicans Candida) is responsible for 36–63% of all can-
didemia reports (Ghaddar etal. 2020). The most commonly isolated non-albicans
was C. glabrata (causing 3%–35% of all candidemia) followed by C. tropicalis
(Negri etal. 2012), C. parapsilosis (Kmeid etal. 2020), C. krusei (Hou etal. 2017),
and other Candida spp. (Law etal. 1996). Furthermore, C. glabrata has propensity
towards decreased susceptibility to uconazole (FLC), while C. krusei is resistant to
FLC (Bodey etal. 2002). There is no signicant difference in antifungal susceptibility of C. albicans and non-albicans spp. except for itraconazole (Pfaller etal. 2014).
C. albicans is a dimorphic fungus that comes in three different forms: yeast cells,
pseudohyphae, and true hyphal cells. Yeast cells are ovoid to circular in shape and
easily distinguished from one another. Pseudohyphae resemble elongated, ellipsoid
yeast cells that develop in a branching pattern and remain attached to one another at
the constricted septation site. True hyphal cells are long, polarized, and have parallel
sides with no constriction between them. When such environmental factors are present, cylindrical outgrowth on the surface of a blastospore begins, forming a germ
tunnel (Hernández-Cervantes et al. 2020). When transitioning from a harmless
commensal organism to a pathogen, Candidia albicans demonstrates remarkable
versatility. “Virulence factors” are surface molecules including adhesins, biolm
formation, hydrolytic enzyme secretion, the ability to change morphology, and metabolic adaptability. By using such virulence factors, Candida spp. can easily adapt
to newer host environment and cause virulence in cases with risk factors (Fig.13.1).
13.3 Antifungal Drugs andResistance
The therapeutic landscape for fungi is dynamic and diversied, with a wide range of
therapeutics. On the basis of their mechanism of action, the numerous drugs currently available to treat fungal infections can be classied into four different categories. Flucytosine, polyenes, allylamines, thiocarbamates, azole derivatives,
morpholines, and other drugs either impede biosynthesis of macromolecules, block
membrane barrier function, prevent ergosterol synthesis, or interact with microtubules (griseofulvin) (Kumar and Jha 2016).
Each pharmacological drug in the above mentioned categories focuses on a dif-
ferent function of the physiology of the fungus in an effort to halt the spread of the
infection. We can categorize the drugs on the basis of their mechanism of action.
Some of the major drugs generally work by impeding the biosysthetic pathways of
vital macromolecules inside the fungal cells. They obstruct the pathogen’s capacity
to reproduce and spread by interfering with this mechanism, which nally stops the
infection. The second group includes drugs that are capable of inhibiting the function of the fungal plasma membrane barrier. This selective interference reduces the
structural integrity of the fungal cell’s outer layer, making it susceptible and encouraging breakdown, both of which are required for infection containment.
13 Candidiasis, Drug Resistance, andTranslational Research
323
Fig. 13.1 General account of various virulence factors of Candida albicans
324
A. Jha and A. Kumar
Drugs that specically target ergosterol production fall under the third group.
Ergosterol is an essential component of the fungal cell membrane, and limiting its
formation affects the cell’s integrity and function, eventually leading to death.
Finally, the fourth group includes drugs that interact with fungal microtubules, with
griseofulvin serving as an example. This interaction disturbs the microtubule network, which is essential for mitosis and replication in fungi. These drugs successfully inhibit fungal growth and division by interfering with this process.
This classication, in essence, emphasizes the complexities of the pharmacologi-
cal treatments used to combat fungal diseases. Each category highlights a distinct
aspect of fungal biology, providing us with a diverse arsenal of medicines to effectively combat these diseases. This classication continues to assist the development
of novel and focused antifungal medicines as our understanding of fungal physiology deepens.
But the phenomenon of multidrug resistance is becoming more common, posing
a global challenge to the successful treatment of bacterial and fungal infections in
humans and animals. The prevalence of infectious complications related to medical
devices is likely to increase as the population ages and the number of devices continues to rise (Kojic and Darouiche 2004). Drug resistance has indeed been described
as the leading cause of therapeutic failure in ucytosine patients. Antifungal drug
resistance refers to fungi’s ability to avoid or become resistant of chemotherapeutic
drugs, antifungal agents, or antibiotics (Cannon and Holmes 2015). This resistance
may be acquired through gene mutation leading to overexpression of drug efux
pump along with other mechanisms. However, unlike bacteria, fungi do not contain
plasmids that can be transferred from one another (horizontal transfer of genes) to
pass on the drug resistance, therefore potential for rapid emergence of drug-resistant
strains is limited if compared to bacteria (Vanden 1997). Finally, translational
research is critical in the advancement of Candida albicans treatments against invasive or systemic candidiasis. Translation research bridges the gap between laboratory ndings and clinical applications, allowing for the creation of novel techniques
to overcome antifungal resistance, improve host immunological responses, and give
individualized treatment options. Researchers, doctors, and pharmaceutical makers
must work together to navigate the complicated terrain of fungal infections and
improve patient outcomes. Translational research remains a driving force in the
development of effective and personalized treatment strategies against this formidable fungal pathogen as our understanding of Candida albicans pathophysiology
evolves.
13.4 Translation Research
Over the last decade, the denition of translational research has broadened, and it
now includes research that helps or encourages the more rapid or efcient transfer
of basic research ndings to large-scale implementation and evaluation for human
applicability. Translational science is unique in the fact that it bridges the gap
between what has historically been considered the domain of the pharmaceutical
13 Candidiasis, Drug Resistance, andTranslational Research
Fig. 13.2 Various portfolio and pillars of translational research
325
and biotechnology industries and that of academia. With growing pressure on the
drug development sector to minimize costs, speed time to market, and reduce attrition rates, fast and efcient translations from one stage of the process to the next
will become even more important. In order to achieve this goal, it is likely that
industry and academia will form further alliances and partnerships (Fig.13.2).
13.4.1 Disease-Oriented Translational Research
In Candida albicans, this research is concerned with elucidating the pathogenesis of
Candida infections, developing diagnostic tools, and developing effective therapies.
This study aims to have a direct impact on patient care by addressing the issues
associated with Candida -related diseases. The following are some of the most
important areas of disease-oriented translational research:
Epidemiology in Clinical Practice
Analyzing patient data to learn about the prevalence, risk factors, and outcomes of
Candida infections in various patient groups. Antifungal resistance and susceptibility patterns are being studied to identify trends.
Diagnostic Progress
Creating rapid and precise diagnostic tests for Candida infections, such as blood
cultures, molecular assays, and antigen detection methods.
Validating the clinical utility of novel early detection diagnostic tools.
326
A. Jha and A. Kumar
Treatment Strategy Optimization
Conducting clinical trials to assess the efcacy and safety of antifungal medications, including established antifungal drugs.
Monitoring of Therapeutic Drugs
Developing therapeutic drug monitoring protocols to ensure optimal antifungal
agent dosing. Drug levels are linked to treatment outcomes and safety proles.
Stratification of Patients
Identifying biomarkers or clinical factors that can classify patients into Candida
infection risk groups and personalizing treatment plans based on patient proles.
Drug Resistance Management
The prevalence and mechanisms of antifungal resistance in clinical isolates are
being studied. Creating strategies for managing and mitigating drug resistance in
clinical settings.
13.4.2 Lab-Oriented Translational Research
Antifungal Drug Development
In the lab, new compounds are screened and tested to identify potential antifungal agents.
Investigating these compounds’ mechanisms of action and resistance.
Drug formulation optimization for improved efcacy and reduced toxicity.
Biomarker Discovery
The discovery of specic biomarkers or molecular signatures linked to Candida
infections. To improve early detection, diagnostic tests based on these biomarkers
are being developed. Using clinical samples to assess the sensitivity and specicity
of these tests.
Analysis of Genomic and Proteomic Data
To better understand Candida albicans strains, genomic and proteomic research is
being conducted. Finding genetic variations linked to drug resistance or virulence.
Investigating the possibility of personalized medicine based on genetic proles.
13.4.3 Patient-Oriented Translational Research
In Candida albicans, the research entails conducting studies and clinical trials that
have a direct impact on the well-being and care of people infected with Candida.
This study aims to improve patient outcomes, improve diagnostics, and develop
patient-centered treatment approaches. Here are some of the most important areas
of patient-centered translational research in Candida albicans:
13 Candidiasis, Drug Resistance, andTranslational Research
327
Clinical Research
Conducting clinical trials in patients with Candida infections to assess the safety
and efcacy of new antifungal drugs, treatment regimens, and therapies. Using realworld patient populations to evaluate the efcacy of combination therapies and
novel agents.
Personalized Healthcare
Creating strategies for tailoring antifungal treatments to individual patient characteristics such as drug susceptibility proles, genetics, and comorbidities.
The impact of personalized treatment plans on patient outcomes and quality of
life is being investigated.
Antifungal Therapy Optimization
Investigating the best antifungal dosing, route of administration, and duration to
maximize efcacy while minimizing side effects. Individual patient therapeutic
drug levels are monitored to ensure proper dosing.
Stratification of Patients
Identifying patient-specic Candida infection risk factors, such as immunosuppression, prior antifungal exposure, and medical procedures. Creating risk-staging models to help guide infection prevention and treatment decisions.
Patient-Reported Outcomes and Quality of Life
Evaluating the impact of Candida infections and treatment on patients’ quality of
life, physical and mental health, and overall well-being. Patient-reported outcomes
are being incorporated into clinical trials and treatment decisions.
Drug Resistance Management
Developing antifungal drug resistance strategies in patients, including therapeutic
options for multidrug-resistant Candida strains.
Vaccines and Immunotherapies
Examining the efcacy and safety of immunomodulatory therapies and vaccines in
real-world patient populations. Evaluating their effectiveness in reducing the frequency and severity of Candida infections in high-risk patients.
Long-Term Monitoring and Survival
The long-term outcomes and survival of patients who have recovered from Candida -related
diseases, particularly those with chronic or recurrent infections, are being tracked.
Developing strategies for dealing with potential complications or sequelae.
Patient Education and Support
Creating patient-centered educational materials and resources to help people with
Candida infections manage their illness. To address the psychosocial aspects of
328
A. Jha and A. Kumar
living with a fungal infection, support networks and counseling services are being
established.
Disease-oriented translational research in Candida albicans is concerned with
elucidating the pathogenesis of Candida infections, developing diagnostic tools,
and developing effective therapies. This study aims to have a direct impact on
patient care by addressing the issues associated with Candida-related diseases. The
following are some of the most important areas of disease-oriented translational
research in Candida albicans:
Epidemiology in Clinical Practice: Analyzing patient data to learn about the
prevalence, risk factors, and outcomes of Candida infections in various
patient groups.
Antifungal resistance and susceptibility patterns are being studied to iden-
tify trends.
Diagnostic Progress: Creating rapid and precise diagnostic tests for Candida
infections, such as blood cultures, molecular assays, and antigen detection methods.
Validating the clinical utility of novel early detection diagnostic tools.
Treatment Strategy Optimization: Conducting clinical trials to assess the efcacy
and safety of antifungal medications, including established antifungal drugs.
Implementing invasive or systemic candidiasis is a major public health concern,
particularly among immunocompromised people and patients undergoing invasive
medical operations. Candida albicans, a commensal yeast found in the human
microbiota, can convert into a dangerous pathogen under specic conditions, producing a variety of illnesses that can be fatal if untreated. The rising prevalence of
antifungal medication resistance has highlighted the critical need for novel therapeutic approaches. Translational research, which serves as a vital link between fundamental scientic ndings and their clinical application, has emerged as a critical
method in the development of Candida albicans medicines. Candida albicans is a
common fungal pathogen in humans. Due to emerging resistance to available antifungals, current treatments are suffering from a massive gap. As a result, there is an
urgent need for novel antifungal Candidates with multiple targets, as most antifungal repertoires are single-target drugs. Multiple-drug targeting in antifungal therapeutics is still being investigated. An extensive literature review was conducted in
order to categorize and comprehend relevant studies as well as the current therapeutic scenario, which prompted researchers to preferentially consider multitarget
drug-based Candida infection therapy. We identied and compiled a few potent
antifungal compounds that are directed toward multiple virulent targets in C. albi-
cans in this article. Such compounds provide an encouraging platform for multiple
targeting and have the potential to have a signicant impact on the development of
effective antifungals. Invasive or systemic candidiasis is a major public health concern, especially among immunocompromised individuals and patients undergoing
invasive medical procedures. To develop more effective antifungal strategies, a thorough understanding of C. albicans virulence properties, as well as genome-wide
gene expression patterns involved in controlling these properties, is required. One
of the most important C. albicans virulence traits is the ability to undergo a morphological transition from single budding yeast cells to pseudohyphal and hyphal
13 Candidiasis, Drug Resistance, andTranslational Research
329
laments (elongated cells attached end-to-end). This reversible transition is induced
in the host environment in response to a wide range of environmental conditions,
including serum, body temperature (37°C), and neutral/alkaline pH. C. albicans
laments promote the invasion of a variety of host tissues, including epithelial and
endothelial cell layers, as well as macrophage lysis. Filamentous growth is also
required for thigmotropism (contact sensing), which is thought to promote C. albi-
cans invasion of weak tissue points (Kumamoto 2008; Jha etal. 2019; Mundodi
etal. 2020).
Global transcriptional proling studies of the C. albicans morphological transi-
tion in response to serum growth at 37°C (one of the strongest lament-inducing
conditions) have revealed that, in addition to genes involved in lamentation, genes
associated with a variety of other virulence properties, such as adhesion to host
cells, degradation of host cell membrane proteins, and response to environmental
stresses, are strongly induced (Chen etal. 2013).
Translational research, which serves as a vital link between fundamental scien-
tic ndings and their clinical application, has emerged as a critical method in the
development of Candida albicans medicines. Furthermore, progress in personalized medicine has had a substantial impact on translational research in Candida
albicans treatments (Walsh etal. 2015). Individual vulnerability to invasive candi-
diasis and response to treatment can be inuenced by genomic proling of both the
infection and the host. Therapeutic techniques that are tailored to a patient’s genetic
make-up can maximize efcacy while avoiding side effects. Finally, translational
research is critical in the advancement of Candida albicans treatments against invasive or systemic candidiasis. Translation research bridges the gap between laboratory ndings and clinical applications, allowing for the creation of novel techniques
to overcome antifungal resistance, improve host immunological responses, and give
individualized treatment options. Researchers, doctors, and pharmaceutical makers
must work together to navigate the complicated terrain of fungal infections and
improve patient outcomes. Translational research remains a driving force in the
development of effective and personalized treatment strategies against this formidable fungal pathogen as our understanding of Candida albicans pathophysiology
evolves.
Another critical part of translational research in Candida albicans therapies is
the investigation of host-pathogen interactions. Understanding how the fungus
evades the host immune response and infects the host is crucial for developing therapies that improve the immune system’s ability to control the infection. Preclinical
studies have showed promise for immunomodulatory methods, which entail modifying the host’s immune response to improve fungus clearance. Translational
research seeks to validate these ndings in clinical trials, with the goal of developing new adjunct medicines that work in tandem with antifungal drugs to improve
patient outcomes.
330
A. Jha and A. Kumar
13.5 Conclusion
Candida albicans, a commensal yeast found in the human microbiota, can convert
into a dangerous pathogen under specic conditions, producing a variety of illnesses that can be fatal if untreated. The rising prevalence of antifungal medication
resistance has highlighted the critical need for novel therapeutic approaches. The
complex interplay between susceptible patients, appropriate environmental circumstances, and fungal proliferation within healthcare facilities emphasizes the need of
understanding the infection cycle. This understanding is the foundation for applying
effective precautions and methods for disease prevention and management. Finally,
translational research is critical in the advancement of Candida albicans treatments
against invasive or systemic candidiasis. Translation research bridges the gap
between laboratory ndings and clinical applications, allowing for the creation of
novel techniques to overcome antifungal resistance, improve host immunological
responses, and give individualized treatment options. Researchers, doctors, and
pharmaceutical makers must work together to navigate the complicated terrain of
fungal infections and improve patient outcomes. Translational research remains a
driving force in the development of effective and personalized treatment strategies
against this formidable fungal pathogen as our understanding of Candida albicans
pathophysiology evolves. This chapter in the book makes a signicant contribution
to uncovering these critical aspects. It also digs into the fundamentals of the fungal
disease Candida albicans. Recent years have seen considerable advancements in
the translational research on Candida albicans and candidiasis. The scientic community is dedicated to solving the growing burden of candidiasis, from unraveling
medication resistance mechanisms to investigating novel therapeutic techniques.
These breakthroughs provide the possibility of more individualized and successful
treatment for patients with Candida albicans infections. The possibilities for better
outcomes for patients with candidiasis are more promising than ever as we continue
to learn more about the intricate host-pathogen relationships and the biology of
fungi of the pathogen’s genomic, metabolomic, and proteomic aspects broadens the
range of information in this domain.
Acknowledgments Authors are thankful to St. Thomas College-Bhilai, Hemchand Yadav
University, Durg (CG), and National Institute of Technology, Raipur (CG), India, for all kinds of
support.
Competing Interests Authors declare that they have no conict of interest.
References
Anderson JB (2005) Evolution of antifungal-drug resistance: mechanisms and pathogen tness.
Nat Rev Microbiol 3:547–556
Arendrup MC, Dzajic E, Jensen RH, Johansen HK, Kjaldgaard P, Knudsen JD et al (2013)
Epidemiological changes with potential implication for antifungal prescription recommen-
13 Candidiasis, Drug Resistance, andTranslational Research
dations for fungaemia: data from a nationwide fungaemia surveillance programme. Clin
Microbiol Infect 19(8):e343–e353
Bhattacharjee P (2016) Epidemiology and antifungal susceptibility of Candida species in a Tertiary
Care Hospital, Kolkata, India. Curr Med Mycol 2(2):20–27
Bodey GP, Mardani M, Hanna HA, Boktour M, Abbas J, Girgawy E etal (2002) The epidemiology
of Candida glabrata and Candida albicans fungemia in immunocompromised patients with
cancer. Am J Med 112(5):380–385
Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC (2012) Hidden killers:
human fungal infections. Sci Transl Med 4(165):165rv13
Cannon RD, Holmes AR (2015) Learning the ABC of oral fungal drug resistance. Mol Oral
Microbiol 30:425
Chakrabarti A, Chatterjee SS, Shivaprakash MR (2008) Overview of opportunistic fungal infec-
tions in India. Jpn J Med Mycol 49(3):165–172
Chen YY, Chao CC, Liu FC, Hsu PC, Chen HF, Peng SC etal (2013) Dynamic transcript prol-
ing of Candida albicans infection in Zebrash: a pathogen-host interaction study. PLoS One
8(9):e72483
Cheng SC, Joosten LB, Kullberg BJ, Netea MG (2012) Interplay between Candida albicans and
the mammalian innate host defense. Infect Immun 80(4):1304–1313
Chi HW, Yang YS, Shang ST, Chen KH, Yeh KM, Chang FY etal (2011) Candida albicans versus
non-albicans bloodstream infections: the comparison of risk factors and outcome. J Microbiol
Immunol Infect 44(5):369–375
Cleveland AA, Harrison LH, Farley MM, Hollick R, Stein B, Chiller TM etal (2015) Declining
incidence of Candidemia and the shifting epidemiology of Candida resistance in two US
metropolitan areas, 2008–2013: results from population-based surveillance. PLoS One
10(3):e0120452
de Pauw BE (2011) What are fungal infections? Mediterr J Hematol Infect Dis 3(1):e2011001.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3103258/. Accessed 23 Apr 2021
Ghaddar N, Anastasiadis E, Halimeh R, Ghaddar A, Dhar R, AlFouzan W etal (2020) Prevalence
and antifungal susceptibility of Candida albicans causing vaginal discharge among pregnant
women in Lebanon. BMC Infect Dis 20(1):32
Gow NAR, Latge JP, Munro CA (2017) The fungal cell wall: structure, biosynthesis, and function.
Microbiol Spectr 5(3). https://doi.org/10.1128/microbiolspec.FUNK- 0035- 2016
Gräser Y, De Hoog S, Summerbell RC (2006) Dermatophytes: recognizing species of clonal fungi.
Med Mycol 44(3):199–209
Gräser Y, Monod M, Bouchara JP, Dukik K, Nenoff P, Kargl A etal (2018) New insights in derma-
tophyte research. Med Mycol 56(suppl_1):S2–S9
Hernández-Cervantes A, Znaidi S, van Wijlick L, Denega I, Basso V, Ropars J et al (2020) A
conserved regulator controls asexual sporulation in the fungal pathogen Candida albicans. Nat
Commun 11(1):6224
Hou X, Xiao M, Chen SCA, Kong F, Wang H, Chu YZ etal (2017) Molecular epidemiology and
antifungal susceptibility of Candida glabrata in China (august 2009 to July 2014): a multicenter study. Front Microbiol 8:880
Jha A, Vimal A, Bakht A, Kumar A (2019) Inhibitors of CPH1-MAP kinase pathway: ascertain-
ing potential ligands as multi-target drug Candida te in Candida albicans. Int J Pept Res Ther
25(3):997
Kennedy MA, Sobel JD (2010 Nov) Vulvovaginal candidiasis caused by non-albicans Candida
species: new insights. Curr Infect Dis Rep 12(6):465–470
Kmeid J, Jabbour JF, Kanj SS (2020) Epidemiology and burden of invasive fungal infections in the
countries of the Arab league. J Infect Public Health 13(12):2080–2086
Kojic EM, Darouiche RO (2004) Candida infections of medical devices. Clin Microbiol Rev
17(2):255–267
Kumamoto CA (2008) Molecular mechanisms of mechanosensing and their roles in fungal contact
sensing. Nat Rev Microbiol 6(9):667–673
Kumar A, Jha A (2016) Anti Candida l agents. Academic Press, NewYork
331